Stockscreener 앱 받기
54.86
4.02%
2.12
시간 외 거래:
54.65
-0.21
-0.38%
전일 마감가:
$52.74
열려 있는:
$52.55
하루 거래량:
2.73M
Relative Volume:
0.87
시가총액:
$4.99B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-19.59
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+5.85%
1개월 성능:
-1.31%
6개월 성능:
+25.14%
1년 성능:
+21.24%
1일 변동 폭
$52.15
$54.94
1주일 범위
$50.83
$55.15
52주 변동 폭
$30.04
$71.13
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
54.86 | 4.80B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
Visual trend scoring systems applied to CRISPR Therapeutics AG2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
With 79% Ownership in CRISPR Therapeutics AG (NASDAQ:CRSP), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
How sentiment analysis helps forecast CRISPR Therapeutics AG - Newser
Invesco Ltd. Cuts Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Does CRISPR Therapeutics AG have pricing powerJuly 2025 Outlook & Risk Managed Investment Strategies - خودرو بانک
Will CRISPR Therapeutics AG benefit from geopolitical trendsPortfolio Performance Report & High Accuracy Swing Entry Alerts - خودرو بانک
Will CRISPR Therapeutics AG stock hit new highs in YEARPortfolio Update Report & Technical Confirmation Trade Alerts - خودرو بانک
Will CRISPR Therapeutics AG benefit from current market trendsJuly 2025 Macro Moves & Long-Term Growth Plans - خودرو بانک
Is CRISPR Therapeutics AG a speculative investment2025 Bull vs Bear & Free Community Consensus Stock Picks - خودرو بانک
Can machine learning forecast CRISPR Therapeutics AG recovery2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Identifying reversal signals in CRISPR Therapeutics AG2025 Dividend Review & Short-Term High Return Ideas - Newser
How hedge fund analytics apply to CRISPR Therapeutics AG stockPortfolio Performance Summary & Capital Protection Trading Alerts - Newser
Will CRISPR Therapeutics AG stock recover after recent dropQuarterly Profit Summary & Weekly High Conviction Ideas - Newser
Zacks Research Has Optimistic Outlook of CRSP Q1 Earnings - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.60 Consensus Price Target from Analysts - MarketBeat
Will breakout in CRISPR Therapeutics AG lead to full recoveryQuarterly Profit Summary & High Accuracy Swing Trade Signals - Newser
Orbis Allan Gray Ltd Buys 86,813 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Real time pattern detection on CRISPR Therapeutics AG stockJuly 2025 PostEarnings & Reliable Price Breakout Alerts - Newser
Why This Biotech Company Could Be a Growth Stock Powerhouse - The Motley Fool
Bank of America Securities Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRISPR Therapeutics AG $CRSP Shares Sold by Baker BROS. Advisors LP - MarketBeat
Forecasting CRISPR Therapeutics AG price range with options dataJuly 2025 Pullbacks & Daily Market Momentum Tracking - Newser
Sentiment analysis tools applied to CRISPR Therapeutics AG2025 EndofYear Setup & Weekly Market Pulse Alerts - Newser
Rafferty Asset Management LLC Trims Stock Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Detecting support and resistance levels for CRISPR Therapeutics AGJuly 2025 WrapUp & Daily Volume Surge Signals - Newser
Multi asset correlation models including CRISPR Therapeutics AGJuly 2025 Earnings & Low Risk Entry Point Guides - Newser
Why is CRISPR Therapeutics AG stock going down2025 Earnings Surprises & Technical Analysis for Trade Confirmation - خودرو بانک
CRISPR Therapeutics Down 5.3% Since Last Earnings Report: Can It Rebound? - AInvest
CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Using Bollinger Bands to evaluate CRISPR Therapeutics AGJuly 2025 Decliners & High Conviction Buy Zone Picks - Newser
Historical volatility pattern of CRISPR Therapeutics AG visualizedTrade Entry Report & High Conviction Trade Alerts - Newser
What machine learning models say about CRISPR Therapeutics AGQuarterly Profit Review & Real-Time Buy Signal Alerts - Newser
Should you wait for a breakout in CRISPR Therapeutics AG2025 Retail Activity & High Return Stock Watch Alerts - Newser
Can technical indicators confirm CRISPR Therapeutics AG’s reversalTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - Newser
CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by Zacks Research - MarketBeat
Is it too late to sell CRISPR Therapeutics AGJuly 2025 Retail & Verified Chart Pattern Trade Signals - Newser
Does CRISPR Therapeutics AG have declining or rising EPSWeekly Market Report & Technical Entry and Exit Alerts - خودرو بانک
Can trapped investors hope for a rebound in CRISPR Therapeutics AGWatch List & Verified Momentum Stock Alerts - Newser
Risk Analysis: Is CRISPR Therapeutics AG part of any major indexJuly 2025 Movers & Precise Entry and Exit Recommendations - خودرو بانک
When is the best time to exit CRISPR Therapeutics AGJuly 2025 Update & Safe Entry Point Alerts - Newser
Statistical indicators supporting CRISPR Therapeutics AG’s strength2025 Dividend Review & Community Shared Stock Ideas - Newser
Technical analysis overview for CRISPR Therapeutics AG stockPortfolio Profit Report & Technical Entry and Exit Alerts - Newser
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
크리스퍼 테라퓨틱스 주식 (CRSP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Treco Douglas A | Director |
Aug 06 '25 |
Buy |
57.03 |
20,000 |
1,140,600 |
22,000 |
| George Simeon | Director |
Jul 16 '25 |
Buy |
52.03 |
989,812 |
51,499,918 |
1,730,179 |
| Patel Naimish | Chief Medical Officer |
May 29 '25 |
Sale |
35.94 |
3,932 |
141,316 |
6,068 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
1.40%
자본화:
|
볼륨(24시간):